Clinuvel Pharmaceuticals (HAM:UR9) Short Interest


HAM:UR9 Clinuvel Pharmaceuticals Ltd HAM:UR9
81 GF Score
Price €5.90
GF Value €10.47
! 2 Warning Signs
View Full Analysis

What is Clinuvel Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

HAM:UR9 vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Short Interest falls into.


HAM:UR9
81GF Score
Clinuvel Pharmaceuticals Ltd HAM:UR9
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Clinuvel Pharmaceuticals (HAM:UR9) Overvalued in 2026?

Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued. The current stock price of €5.90 is trading 43.6% below its estimated GF Value™ of €10.47.

Key valuation signals for HAM:UR9:

  • Short Interest:
  • GF Value™: €10.47 vs. price of €5.90 (43.6% below fair value)
  • GF Score™: 81/100 with 2 warning signs

No single metric tells the full story. See the HAM:UR9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinuvel Pharmaceuticals Business Description

Address 535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
81GF Score

Get the complete analysis for HAM:UR9

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.90
Price
€10.47
GF Value